The acquisition of Texas-based IntraBio adds to a growing rare disease business for Shionogi by handing the company a ...
The company’s next-generation shot surpassed Wall Street’s expectations by matching the effectiveness of vaccines from Pfizer ...
The Nobel laureates “laid the foundation” for a new field of brain research, the award committee wrote. Elsewhere, Roche and ...
The deal carries a $1 billion upfront payment and tasks the two companies to develop long-acting antibody drugs that go after ...
Zepbound combination data. Elsewhere, Novo demonstrated continued weight loss following a switch to oral and AbbVie and ...
The latest installment in BioPharma Dive’s data visualization series features a closer look at Kodiak’s stock performance and ...
A former congressman will take over for prominent lobbyist Steve Ubl. Elsewhere, recent buyout deals paid dividends for Mirum and AbbVie.
The pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.
The FDA previously hadn’t ever accepted an application of a drug like fenebrutinib in two major forms of MS. But safety ...
The department is offering funding to teams with innovative proposals as it considers ending the traditional phased clinical trial system.
In exchange for a $575 million payment up front, Abogen Biosciences will furnish Novartis with access to its RNA technology, including an option to license its lead program ABO-2203.
A spokesperson confirmed that a “limited number” of liver-related safety events, including a patient death, were observed in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results